FGF2 and non-small cell lung carcinoma: Our results have also identified increased FGFR1 activity as a key mediator of palbociclib resistance in KRAS-mutant NSCLC, which was due to secretion of bFGF and linked to elevated ERK and mTOR signaling, as well as increased expression of CDK6 and D-type cyclins.